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INTRODUCTION
Human skeletal muscle is a heterogeneous tissue composed of multiple fiber types (FT) categorized by myosin heavy chain (MHC) isoform content into three pure [slow, MHC I; fast, MHC IIa; and superfast, MHC IIx] and three hybrid (MHC I/IIa, MHC IIa/IIx, and MHC I/IIa/IIx) types that express unique contractile and metabolic properties (11, 38, 39, 43) . The relative abundance of each FT varies significantly between individuals and depends on numerous factors such as exercise history, age, and health status (3, 18 -20, 26, 45) . Thus the need to distinguish and account for FT in studies of human muscle is considerable (31) . Unfortunately, the majority of human skeletal muscle research analyzes mixed FT samples, creating major gaps in our understanding of the properties specific to each FT. Notable investigations have indeed implemented FT-specific protein measurements with success (10, 12, 13, 21-23, 32, 44) . However, they predominantly limited their analyses to pure FT (i.e., MHC I, MHC IIa, and/or MHC IIx) without consideration of hybrids. Moreover, these studies were restricted by Western blotting (WB) limits of detection for quantifying specific proteins from singlefiber samples. Investigators enabled protein detection either through pooling 20ϩ fibers of similar type (10, 13, 21) or through dissolving single fibers in small buffer volumes (5-10 l; 12, 22, 23, 32) to generate sufficient sample concentrations. The smallvolume, single-fiber approach reduces resource requirements and human error risk (32, 33) yet constricts sample supply. The limitations of WB detection and time-intensive nature of FTspecific methods likely dissuade implementation of FT-specific studies altogether (31) .
Capillary nanoimmunoassay (CNIA) is a recently developed, innovative alternative to WB. This technology quantifies proteins using the same separation and antibody detection principles (7, 8) , yet improves upon several limitations of WB. CNIA significantly reduces the amount of sample needed, fully automates the assays, and reduces the assay time from 2 days to 3-6 h (7, 8) . The detection of proteins within the microscale dimensions provided by a capillary permits analysis of protein levels significantly lower in sample concentration than WB (7) thus holding great promise for application to single-fiber studies. CNIA has recently been evaluated for improving cancer diagnostics by solving similar methodological issues inherent with limited-supply patient samples (14, 36) . However, CNIA has not yet been applied to the study of human muscle, nor has it been explored as a viable option for FT-specific analyses.
An excellent protein candidate for this assessment is 5=-AMP-activated protein kinase (AMPK). This energy-sensing master regulator of cellular metabolism is activated physiologically during acute exercise to regulate both short-term energy homeostasis signaling (35) and long-term metabolic adaptations through initiation of gene expression programs (6, 17, (27) (28) (29) . The kinase is an evolutionary conserved ␣␤␥-heterotrimer consisting of three subunits: catalytic (␣), scaffolding (␤), and regulatory (␥). Human skeletal muscle expresses seven known AMPK subunit isoforms: ␣ 1 , ␣ 2 , ␤ 1 , ␤ 2 , ␥ 1 , ␥ 2 , and ␥ 3 (9, 21, 29, 47) . FT-specific studies employing WB methods have shown that certain AMPK isoforms are expressed differently in MHC I vs. MHC II fibers (21, 24, 32) . However, none have included the analysis of hybrid FT.
In this investigation, we developed and assessed novel methods for FT-specific protein quantification that reduce resource requirements and improve measurement precision using the study of AMPK isoforms as a proof of concept. We first compared relative specific protein quantification between CNIA and WB and then combined CNIA with a previously established comprehensive single-fiber typing method (SDS-PAGE) to perform FT-specific analysis. These novel methods enabled the comparison of AMPK isoform expression in both pure (MHC I and MHC IIa) and hybrid (MHC I/IIa and MHC IIa/IIx) FT. Our data support the use of these methods as a powerful tool to advance the field of molecular FT-specific study of human skeletal muscle.
METHODS

Materials and antibodies.
Reagents and supplies for CNIA procedures were obtained from ProteinSimple (San Jose, CA). All other chemicals used were from Thermo Fisher Scientific (Waltham, MA) or Sigma-Aldrich (St. Louis, MO), unless otherwise stated. Primary antibodies for AMPK-␣ 2 (no. 2757), -␤1 (no. 4178 and 12063), -␤2 (no. 4148 and 4150), -␥3 (no. 2550), and tubulin (no. 2125) were purchased from Cell Signaling Technology (Danvers, MA). The antibody for AMPK-␣ 1 (ab32047) was from Abcam (Cambridge, MA), and the antibody for AMPK-␥ 2 (NBP1-89324) was from Novus Biologicals (Littleton, CO). Secondary horseradish peroxidase (HRP)-conjugated anti-rabbit IgG antibodies were from Cell Signaling Technology (no. 7074 for WB) and ProteinSimple (no. 042-206 for CNIA).
Muscle biopsy. Muscle tissue was collected from the resting vastus lateralis muscle of a 32-yr-old female, eumenorrheic, previously trained (maximal oxygen consumption ϭ 44.6 ml·kg Ϫ1 ·min Ϫ1 , measured as 15-s average on cycle ergometer) single subject on day 32 of her menstrual cycle. Training consisted of 2-3 days/wk of aerobic exercise and 3-4 days/wk of resistance exercise for 6 mo before the study. The participant arrived at the laboratory after an overnight (12 h) fast and rested in a supine position for 30 min. A mark was made mid-muscle belly (halfway between the greater trochanter and patella), cleaned with iodine, and anesthetized with 1% lidocaine/ xylocaine. A small incision was made, and then tissue (~100 mg) was obtained using the Bergström technique (5) with applied suction as described previously (1, 2, 30) . The muscle sample was immediately cleansed of excess blood, fat, and connective tissue, cut into multiplẽ 15-mg bundles, rapidly frozen in liquid nitrogen, and stored at Ϫ80°C until dissection. The incision site was cleaned and covered with sterile gauze and cohesive bandage tape. All human subject procedures were approved by the Institutional Review Board, and the participant signed an informed consent document before participation. Isolation and preparation of single muscle fibers. Tissue samples were incubated in RNAlater-ICE for at least 48 h at Ϫ20°C before transfer to storage in RNAlater at Ϫ20°C. Segments (~5 mm long) of 312 individual randomly selected fibers were mechanically isolated on ice using fine tweezers under a light microscope in 7 mM EGTA, 20 mM imidazole, 5 mM MgCl 2, 80 mM KCl, and 16 mM CaCl2, pH 6.9, with Halt protease and phosphatase inhibitor cocktail added at 1:100 dilution. Isolated single fibers were placed separately in 15 l of buffer A (62.5 mM Tris, 2% SDS, 23 mM EDTA, 5% glycerol, and 715 mM ␤-mercaptoethanol, pH 6.8), incubated at 95°C for 5 min to solubilize and denature proteins, flash-frozen in liquid nitrogen, and stored at Ϫ80°C until analysis. For the pooled fiber sample used in WB vs. CNIA comparison analysis, 40 individual fibers of mixed FT were isolated and dissolved together in 80 l of buffer B (1% SDS, 23 mM EDTA, 10% glycerol, and 400 mM ␤-mercaptoethanol, pH 6.8), solubilized, and stored at Ϫ20°C until analysis.
Identification of muscle fiber type. One-microliter aliquots of each dissolved fiber sample were diluted 1:8 in buffer C (0.008% bromophenol blue, 1% SDS, 23 mM EDTA, 15% glycerol, and 715 mM ␤-mercaptoethanol, pH 6.8). Then, 1.5 l of each sample in buffer C were loaded into individual wells of a 3.5% stacking and 5% separating polyacrylamide gel and run at 150 V and 5°C (SE 600 Series; Hoefer, San Francisco, CA) for 15 h using buffer D (192 mM glycine, 25 mM Tris base, and 0.1% SDS). Gels were subsequently fixed, rinsed, and silver stained to reveal each MHC isoform expressed from each individual fiber according to migration distance. FT was then identified as MHC I, I/IIa, IIa, IIa/IIx, IIx, or I/IIa/IIx (30) .
Selection of fibers and loading equalization for FT-specific study. Twelve to 18 single-fiber samples were selected for each of the following 4 FT: MHC I, MHC I/IIa, MHC IIa, and MHC IIa/IIx. The FT for these samples was confirmed with an additional SDS-PAGE gel run and silver stain. Two fiber samples stored in buffer A of the same type were then combined together. An initial CNIA run with an antibody for tubulin was performed using the procedures described below in Capillary nanoimmunoassay. Sample volumes were adjusted with buffer A according to tubulin measurements to achieve relative equal loading. A second CNIA run with the tubulin antibody was performed on the adjusted samples for quantification of relative AMPK expression.
Capillary nanoimmunoassay. All reagents and supplies used for CNIA procedures were acquired from the manufacturer for use on the commercially available Wes Simple Western platform (ProteinSimple). This instrument uses 25 individual capillaries per run that are 5 cm in length and 100 m in inner diameter. These capillaries employ a patented inner coating that allows separation, capture, covalent immobilization, and subsequent immunodetection of proteins from a wide array of species samples. All assay steps are performed in a 400-nl volume within a single capillary. Samples, antibodies, and detection reagents are all housed and accessed from a microtiter plate. Chemiluminescence is employed as a means of detection. A fluorescently labeled master mix was added to the diluted fiber samples at 20% of total volume. Three microliters of prepared reduced/denatured sample were loaded into each of the sample wells of the 25-sample capacity, 12-230-kDa microtiter plate (prefilled with running buffer, stacking matrix, and separation matrix) along with 10 l of diluted primary antibody into separate corresponding wells. Primary antibodies were diluted from their manufactured stocks as follows: 1:20 (anti-AMPK-␣2, -␤1, -␤2, and -␥3), 1:25 (anti-tubulin), 1:50 (anti-AMPK-␣1), and 1:10 (anti-AMPK-␥2). Prior to the study, each antibody was validated for optimal concentration using a calibration curve of serial fiber dilutions to ensure linearity of signal quantification. The plate was also loaded with antibody dilution buffer, secondary HRP-conjugated anti-rabbit IgG antibody, chemiluminescent substrate reagents, and wash buffer. A biotinylated molecular weight ladder and a streptavidin-HRP conjugate were loaded into the first lane as instructed by the manufacturer for size determination. Incubation times for the AMPK-␤1 and AMPK-␥2 primary antibodies were set at 4 h to optimize their signal-to-noise ratios (S/N) while all other antibodies were run for 30 min. The antibodies for AMPK-␣2 and AMPK-␤2 were combined in a single multiplex run based on the high specificity and minimal background of these particular antibodies and the molecular weight separation of their targets. Quantification of electropherograms was performed with Compass for SW software (v3.1.7; ProteinSimple) using a Gaussian peak fit distribution for area under the curve.
Total protein assay. Total protein concentration was measured for the pooled fiber sample using a Bradford assay. The sample was diluted 1:100 into a 96-well plate and stained 1:1 with a detergentcompatible Bradford assay reagent. Measurements were performed in triplicate using 595-nm wavelength on a SpectraMax M3 plate reader (Molecular Devices, Sunnyvale, CA) with a linear standard range of 2.5-25 g/ml BSA.
Western blotting. The pooled fiber sample (0.5 fibers/l) was analyzed using both WB and CNIA. The starting stock was diluted in buffer B to various fiber concentrations and combined with 20% buffer C for WB analysis. Samples were run on an 8% separating polyacrylamide gel at 200 V for 90 min using buffer D and wet transferred to polyvinylidene difluoride membrane for 3 h at 80 V using a transfer buffer containing 192 mM glycine, 25 mM Tris base, and 20% methanol. Immediately following transfer, membrane was blocked for 60 min in 5% nonfat milk powder (Bio-Rad, Hercules, CA) dissolved in buffer E (20 mM Tris base, 150 mM NaCl, and 0.05% Tween 20). Membrane was then rinsed three times for 5 min each in buffer E and rocked overnight at 4°C in primary antibody diluted in 5% BSA in buffer E. Following another round of rinsing three times in buffer E, membrane was then rocked at room temperature for 90 min in secondary antibody diluted 1:2,000 in 5% nonfat milk in buffer E. Following a final round of rinsing three times in buffer E, membrane was developed with SuperSignal West Femto enhanced chemiluminescent (ECL) substrate diluted 1:10 in SuperSignal West Pico ECL substrate and imaged using an Omega Lum C imaging system (Aplegen Gel, San Francisco, CA). Densitometry analysis was performed using ImageJ software (National Institutes of Health, Bethesda, MD, public domain).
Statistical analysis. Data are expressed as means Ϯ SE. Ordinary one-way analysis of variance (ANOVA) followed by Tukey's multiple-comparison test was performed using GraphPad Prism software. Significance was set at P Ͻ 0.05.
RESULTS
Relative detection limits for capillary nanoimmunoassay and Western blotting.
A sample containing 40 fibers of mixed type was prepared in 80 l of buffer A to a concentration of 0.5 fibers/l with measured total protein content of 1.57 mg/ml. A seven-point dilution series was generated down to a minimum concentration of 0.00625 fibers/l. Aliquots were individually prepared for CNIA or WB by adding either 20% of the fluorescently labeled master mix (CNIA) or 20% buffer C (WB) to final concentrations ranging from 0.005 to 0.4 fibers/ l. Detection of AMPK-␤ 2 was then performed using the same Listed fiber concentrations are for prepared samples containing 20% buffer C run on Western blot (WB) or 20% 5X fluorescent master mix run on capillary nanoimmunoassay (CNIA). Total protein concentration was measured for the starting stock (0.5 fibers/l) via Bradford assay and then calculated for all dilutions prepared from this stock. Chemiluminescent signals were calculated as the area under the 5=-AMP-activated protein kinase ␤2-isoform (AMPK-␤2) peak using ImageJ software for WB and Compass software for CNIA. An x denotes dilutions that were below the limit of detection for each method. A signal-to-noise ratio (S/N) was calculated for CNIA measurements via Compass software.
antibody for both methods. AMPK-␤ 2 resolved at 30 kDa on WB only at concentrations of 0.2 fibers/l and above (Fig. 1A) and was linear in its quantification for three measured concentrations (Fig. 1B) . AMPK-␤ 2 showed detection on CNIA down to 0.01 fibers/l (Fig. 1C) with linear quantification for six measured concentrations up to 0.3 fibers/l. AMPK-␤ 2 quantification at 0.4 fibers/l surpassed the upper limits for linear range of the assay (Fig. 1B) while detection at 0.01 fibers/l pressed the lower limits of CNIA quantification with a S/N of 14 (Table 1) . AMPK-␤ 2 exhibited an apparent molecular weight of 30 kDa by WB and 40 kDa by CNIA with no nonspecific peaks detected across the entire 12-230-kDa range on CNIA (Fig. 1C) .
Comparisons of apparent molecular weight for AMPK isoforms. The apparent (APP) molecular weights (MW) observed with CNIA for each AMPK isoform in human muscle are listed in Table 2 compared with 1) predicted human MW listed by UniProt, 2) APP MW observed with WB in cell cultures listed by antibody manufacturers' data sheets, and 3) APP MW observed with WB in human muscle fibers from previous publications (21, 32, 47) . The AMPK ␤ 1 -and ␤ 2 -isoforms exhibited the greatest shifts in APP MW from their predicted MW (Table 2 ). These isoforms were each measured with two different antibodies directed against different epitopes that resolved the same APP MW to confirm antibody specificity (Fig. 2) . The predicted molecular weight (MW) measured in kDa for each human 5=-AMP-activated protein kinase (AMPK) isoform (␣1, ␣2, ␤1, ␤2, ␥2-subisoform A, and ␥3) as listed by UniProt is compared against various apparent (APP) MW found in cell cultures as listed on data sheets from antibody manufacturers and in human muscle fibers from previous publications, all determined by Western blot (WB). An x indicates that the isoform was not studied in a publication. The final column lists APP MW values determined by capillary nanoimmunoassay (CNIA) in human muscle fibers in the present study. *Antibodies (indicated by catalog number) and APP MW used in the present study to measure FT-specific AMPK isoform expression. Fiber typing. The methods used to identify FT are shown in Fig. 3 , using the shifts in the distinct bands that represent the presence of MHC I, IIa, and IIx isoforms in each single fiber. The overall FT composition of the subject was 45% MHC I, 13% MHC I/IIa, 31% MHC IIa, 9% MHC IIa/IIx, 2% MHC I/IIa/IIx, and 0% MHC IIx from the typing of 830 single fibers (pie chart in Fig. 3 ). The analysis of 312 fibers applying the procedures outlined in Fig. 3 was enough to obtain at least 16 single-fiber samples of each FT for measurements of AMPK isoform expression except for the rarest FT, MHC I/IIa/IIx and MHC IIx, thus excluding them from study.
Fiber type-specific AMPK isoform expression. Subunit isoform expression was measured for six AMPK isoforms: catalytic subunits ␣ 1 and ␣ 2 (Fig. 4) , scaffolding subunits ␤ 1 and ␤ 2 (Fig. 5) , and regulatory subunits ␥ 2 and ␥ 3 (Fig. 6) , with tubulin as a standard loading control. AMPK-␣ 1 expression exhibited a slight, but nonsignificant (P ϭ 0.107), increase in MHC I vs. MHC IIa/IIx fibers (Fig. 4, A-C) . AMPK-␣ 2 expression was significantly higher (1.7-fold) in MHC IIa and IIa/IIx compared with MHC I and I/IIa (P Ͻ 0.05, Fig. 4 , D-F). AMPK-␤ 1 expression was 1.5-fold higher in MHC IIa vs. MHC I fibers (P Ͻ 0.05), with no significant differences in the hybrid fiber types (Fig. 5, A-C) . AMPK-␤ 2 was 1.5-fold higher in MHC IIa/IIx fibers vs. MHC I/IIa fibers (P Ͻ 0.05) yet was equivalent in MHC I and IIa (Fig. 5, D-F) . AMPK-␥ 2 was significantly higher in MHC IIa fibers vs. all three other FT, being 2.5-fold higher vs. MHC I and IIa/IIx fibers and 1.8-fold higher than MHC I/IIa fibers (Fig. 6 , A-C, P Ͻ 0.01). AMPK-␥ 3 was twofold higher in MHC IIa vs. MHC I fibers and fourfold higher in MHC IIa/IIx fibers (Fig. 6 , D-F, P Ͻ 0.01).
DISCUSSION
The methodologies presented in this paper build upon prior innovative works (21, 32) and contribute further advancement in human skeletal muscle FT-specific research. The primary purpose of this investigation was to assess the viability of using CNIA combined with single-fiber SDS-PAGE analysis of MHC as a novel method for FT-specific protein quantification. The main advantages of this approach are the 1) ability to detect proteins from significantly lower fiber concentrations than WB, 2) inclusion of hybrid (MHC I/IIa and IIa/IIx) FT, and 3) speed, automation, and precision of protein assessment enabled by CNIA. The application of this approach to the study of FT-specific AMPK isoform expression yielded results that either 1) reproduced previous study findings, 2) found significant FT-specific differences not previously detected with WB, Fig. 3 . Schematic of methods used to measure fiber type (FT)-specific 5=-AMP-activated protein kinase (AMPK) expression. A cleansed biopsy sample was immediately cut into bundles, frozen in liquid nitrogen, and stored at Ϫ80°C. Following incubation in RNAlater-ICE for 48ϩ h, then storage in RNAlater at Ϫ20°C, individual fibers were isolated from the bundles, dissolved in separate tubes containing 15 l of denaturing buffer, and boiled at 95°C for 5 min. An aliquot of 1 l from each indexed single-fiber sample was diluted 1:8 in a separate buffer for SDS-PAGE analysis of FT via myosin heavy chain (MHC) molecular weight detected via silver staining. Overall FT composition was determined via percentages of each identified FT (pie chart). The original samples were then combined together in pairings of the same FT and analyzed on capillary nanoimmunoassay (CNIA) for relative tubulin content (loading control). Samples were then diluted accordingly to achieve relative even loading and combined with 20% fluorescently labeled master mix. CNIA analysis was then performed on 24 individual samples of 6 replicates for each FT in separate runs using 3 l of sample for each protein target.
or 3) added new data on the previously unstudied hybrid FT and AMPK ␥ 2 -isoform. The ability of CNIA to significantly lower the AMPK detection limit (~20-fold lower than WB) allows for specific protein measurements at lower sample concentrations, thus better enabling the analysis of single muscle fibers. In the present study, we chose to combine two dissolved fibers of the same FT to generate the sample volume needed to analyze multiple AMPK isoform targets. However, the described methods could indeed be used for the study of fewer targets from single-fiber samples if desired. Detection of specific proteins from lower fiber concentrations represents a major advancement from previous studies that achieved WB detection at higher fiber concentrations (10, 13, 21, 32) because it lowers the costs, time, and tissue requirements. CNIA also has the additional advantages of 1) a S/N reading for each peak, providing the investigator better information regarding limits of quantification, 2) the ability to directly compare different concentrations of the same antibody to optimize its performance (via S/N), 3) better reproducibility of results through automation, and 4) consistency and speed of operation compared with WB (8). Full automation is achieved because sample loading, protein separation, immobilization by ultraviolet light, and antibody probing are all performed by the instrument within the capillary. These factors combine to yield reproducible quantification for a wide range of proteins with good precision (coefficients of variation Ͻ15%; 7, 8).
One advantage of WB that CNIA lacks, however, is the ability to cut a blot and separately analyze different targets via multiple antibodies from the same sample lane, requiring only that the targets be sufficiently separated by molecular weight (MW). In the case of CNIA multiplexing, the primary antibodies for separate targets are mixed together to analyze multiple targets in the same capillary, as performed for AMPK-␣ 2 and -␤ 2 in the present study. This combination requires careful validation to ensure that the antibodies do not significantly interfere with each other's performance. Investigators may be limited to performing single-target capillary analyses if the antibodies have high background or off-target effects, increasing the number of separate instrument runs for the study of multiple antibody targets.
An additional discrepancy between WB and CNIA is the apparent (APP) MW observed for a particular antibody target. APP MW can differ from predicted MW when resolved on either technique, thus occasionally presenting uncertainty regarding the identity of the detected protein due to questionable antibody specificity. Some proteins exhibit little or no change from their predicted MW on WB or CNIA, as observed for the catalytic subunit isoforms ␣ 1 and ␣ 2 in the present study. Other proteins can exhibit APP MW shifts of 10 kDa or more between WB and CNIA, as observed with the scaffolding isoforms ␤ 1 and ␤ 2 . APP MW can be altered by several factors including protein-specific posttranslational modifications (40, 41) , the particular cell system used for protein expression, the formulation of the gel used for protein separation (15, 16, 37) , and the particular ladder used to resolve the MW of the detected target. Thus MW shifts observed with CNIA (which uses a different separation matrix from that of WB) are reasonable and in accordance with effects seen in other gel separation methods. However, larger shifts in APP MW more commonly exhibited by CNIA may require more frequent confirmation of the specificity for a particular antibody, requiring additional tests using other controls. The largest shifts in MW in the present study were observed for AMPK-␤ 1 and -␤ 2 and were confirmed with alternate primary antibodies directed against different epitopes that produced the same APP MW peaks. A reliable, effective, and sample-conserving method of quantifying total protein in single-fiber samples remains challenging for the normalization of sample loading in both CNIA and WB, yet important because of the heightened variability in protein content present in individual fibers of differing lengths and thicknesses. Standard total protein assays typically have lower sensitivity compared with specific immunoassays, thus limiting effective detection in samples with low concentrations. We evaluated multiple methods for measuring total protein content from single-fiber samples using 1) the Bradford assay via plate reader, 2) silver staining on an 8% SDS-PAGE gel, and 3) CNIA total protein detection using biotin labeling with a streptavidin-HRP conjugate (data not shown). All three methods failed to achieve adequately equal loading control normalization (tubulin levels) between samples and had additional disadvantages of either requiring large quantities of sample (Bradford assay) or predominance of a single protein for measurement (silver stain and biotin labeling). We thus chose to normalize sample loading on the basis of an initial tubulin CNIA analysis and subsequently performed a second tubulin analysis for a loading control in quantification. Tubulin has precedence in this capacity for FT-specific study (42, 46) , whereas other common loading controls such as GAPDH exhibit known FT dependency (13) . Actin and MHC have also been applied as FT loading controls (21, 22, 32, 44) . However, their high abundance in muscle fibers requires careful evaluation of their linear range of quantification (33) and further sample dilution than for AMPK or tubulin analysis. In the present analysis of AMPK expression, multiple FTspecific differences were observed across all isoforms studied. The catalytic subunit ␣1 displayed a slight, but nonsignificant, inclination toward higher expression in slow-twitch fibers vs. faster-twitch fibers. Previous FT-specific studies of ␣ 1 report conflicting findings as one showed slightly higher expression in MHC I fibers (32), while another found equivalent expression (21) . Endurance athletes, who typically express more MHC I fibers, were also shown to express more AMPK-␣ 1 in mixed-FT muscle samples than sedentary controls (34) . On the other hand, our data suggest that AMPK-␣ 2 was significantly more abundant in the fast-twitch types (MHC IIa and IIa/IIx), a result not observed in previous FT-specific studies using WB (21) . Methodological differences could explain this confliction, as the difference in ␣ 2 expression may have been within the margin of error for WB, yet was resolved with the increased precision of CNIA. The scaffolding subunit ␤ 1 exhibited a lower expression in MHC I vs. MHC IIa fibers. This result contrasts with previous studies that had shown higher expression of ␤ 1 in MHC I fibers from men (21, 32) . A difference in subject sex possibly explains the conflicting findings, but an alternative study design is necessary to test this speculation. The expression of scaffolding subunit ␤ 2 was equivalent in MHC I and MHC IIa fibers, agreeing with previous findings (21) and supporting the use of tubulin as a FT loading control. However, significant differences between the hybrid FT, MHC I/IIa vs. IIa/IIx, were observed for ␤ 2 , which were not examined in previous investigations.
The most striking FT-specific results were observed for the regulatory subunits AMPK-␥ 2 and -␥ 3 . In particular, dramatic differences between MHC IIa and IIa/IIx fibers were observed for both isoforms, being significantly higher in MHC IIa vs. IIa/IIx for ␥ 2 and exhibiting the opposite relationship for ␥ 3 . AMPK-␥ 2 is rarely studied in human skeletal muscle and is the only isoform lacking previous human FT-specific study, yet it is the most AMP-sensitive regulatory isoform as shown through in vitro studies (9) . In contrast, the FT dependency of AMPK-␥ 3 has been studied both in human MHC I vs. II fibers (21, 24) and in rodent slow-vs. fast-twitch muscles (4, 25) , with all studies observing higher expression in fast-twitch muscle. The present addition of data expanding the FT spectrum of ␥ 3 expression demonstrates its correlation with the contractile power of the fiber (13) . Expression is lowest in slow-twitch fibers (MHC I and I/IIa), higher in MHC IIa, and highest in the fastest type, IIa/IIx. This behavior further supports the glycolytic preference of this isoform, the only AMPK isoform that is exclusively expressed in skeletal muscle tissue (9) . Taken together, these data highlight the importance of studying both the pure and hybrid FT. They also demonstrate the efficacy of the presented methods in distinguishing between MHC IIa and IIa/IIx single-fiber samples, a distinction not possible through typing methods that rely on pan-specific antibodies for MHC II (32) or in immunohistochemistry methods that lack the ability to resolve hybrid FT (24) .
The necessity for FT-specific analysis of human muscle has been advocated by others (31) and demonstrated through numerous studies of multiple protein targets (10, 12, 13, 21-23, 32, 44) . Previous methods for performing FT-specific measurements have been laborious and limited, ultimately dissuading researchers from undertaking FT-specific investigations. To our knowledge, this paper is the first to utilize CNIA technology for measurement of protein expression in human muscle fibers, demonstrating its significant advantages in lowering limits of detection and facilitating single-fiber analyses. The robust, effective, and expedient methods presented in this paper will further encourage future FT-specific study of human skeletal muscle, thus enabling better understanding of metabolism and muscle physiology.
